CN100430089C - 美拉加群在制造治疗i型糖尿病的药物中的用途 - Google Patents

美拉加群在制造治疗i型糖尿病的药物中的用途 Download PDF

Info

Publication number
CN100430089C
CN100430089C CNB038026740A CN03802674A CN100430089C CN 100430089 C CN100430089 C CN 100430089C CN B038026740 A CNB038026740 A CN B038026740A CN 03802674 A CN03802674 A CN 03802674A CN 100430089 C CN100430089 C CN 100430089C
Authority
CN
China
Prior art keywords
cells
melagatran
prodrug
insulin
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038026740A
Other languages
English (en)
Chinese (zh)
Other versions
CN1729010A (zh
Inventor
O·科尔斯格伦
B·尼尔松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1729010A publication Critical patent/CN1729010A/zh
Application granted granted Critical
Publication of CN100430089C publication Critical patent/CN100430089C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB038026740A 2002-01-23 2003-01-21 美拉加群在制造治疗i型糖尿病的药物中的用途 Expired - Fee Related CN100430089C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE02001980 2002-01-23
SE0200198-0 2002-01-23
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use

Publications (2)

Publication Number Publication Date
CN1729010A CN1729010A (zh) 2006-02-01
CN100430089C true CN100430089C (zh) 2008-11-05

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038026740A Expired - Fee Related CN100430089C (zh) 2002-01-23 2003-01-21 美拉加群在制造治疗i型糖尿病的药物中的用途

Country Status (14)

Country Link
US (2) US7045502B2 (https=)
EP (1) EP1469874A1 (https=)
JP (1) JP2005516035A (https=)
KR (1) KR20040075096A (https=)
CN (1) CN100430089C (https=)
BR (1) BR0306798A (https=)
CA (1) CA2472241A1 (https=)
IL (1) IL162853A0 (https=)
MX (1) MXPA04007192A (https=)
NO (1) NO20043483L (https=)
NZ (1) NZ533749A (https=)
SE (1) SE0200198D0 (https=)
WO (1) WO2003061682A1 (https=)
ZA (1) ZA200405342B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
CN107405333A (zh) 2015-02-27 2017-11-28 维颂公司 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物
CN113164765B (zh) 2018-07-13 2026-03-20 维颂国际公司 凝血酶抑制剂、制剂及其用途
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041716A1 (en) * 1999-01-13 2000-07-20 Astrazeneca Ab New use of melagatran

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041716A1 (en) * 1999-01-13 2000-07-20 Astrazeneca Ab New use of melagatran

Also Published As

Publication number Publication date
CA2472241A1 (en) 2003-07-31
US7045502B2 (en) 2006-05-16
EP1469874A1 (en) 2004-10-27
IL162853A0 (en) 2005-11-20
US20050090424A1 (en) 2005-04-28
WO2003061682A1 (en) 2003-07-31
NZ533749A (en) 2006-02-24
SE0200198D0 (sv) 2002-01-23
BR0306798A (pt) 2004-12-07
KR20040075096A (ko) 2004-08-26
NO20043483L (no) 2004-08-20
JP2005516035A (ja) 2005-06-02
US20060148720A1 (en) 2006-07-06
CN1729010A (zh) 2006-02-01
ZA200405342B (en) 2005-09-28
MXPA04007192A (es) 2004-10-29

Similar Documents

Publication Publication Date Title
Ozmen et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation
Lakey et al. Current status of clinical islet cell transplantation
US20230033991A1 (en) Neo-Islets Comprising Stem and Islet Cells and Treatment of Diabetes Mellitus Therewith
Nijhoff et al. Glycemic stability through islet-after-kidney transplantation using an alemtuzumab-based induction regimen and long-term triple-maintenance immunosuppression
CN100430089C (zh) 美拉加群在制造治疗i型糖尿病的药物中的用途
CA2481184A1 (en) Medicament for preventing and/or treating chronic rejection
KR100828807B1 (ko) 새로운 용도의 덱스트란 설페이트
US7659249B2 (en) Membrane-permeable NFAT inhibitory peptide
JP2021516052A (ja) 胸腺組織に由来する制御性ｔ細胞を入手する方法および免疫系障害における細胞免疫療法としての前記細胞の使用
US8048411B2 (en) Co-transplantation of hepatic stellate cells and islet cells
CN114762725B (zh) 一种治疗糖尿病的方法
CN114762697B (zh) 用于治疗糖尿病的药物及方法
US20050255111A1 (en) Use of an inhibitor or antagonist against tissue factor
AU2003202192A1 (en) The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus
Mineo et al. Islet and pancreas transplantation
Mattke Targeting Toll-Like Receptor 4 Related Inflammation Using Small Molecule, TAK-242, to Attenuate Inflammatory Damage in Pancreatitis and Islet Transplantation
Harlan Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression
JP2024506001A (ja) 幹細胞及び膵島細胞を含む細胞クラスター、当該細胞クラスターを作製する方法、並びに当該細胞クラスターを用いた糖尿病の治療
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
Smetanka et al. Islet Cell Transplantation
McCall Enhancing engraftment of islets of Langerhans and other cellular therapies for diabetes
Aiso et al. BENEFICIAL EFFECT OF FR167653, A p38 MITOGEN-ACTIVATED PROTEIN KINASE INHIBITOR, ON EARLY POST-TRANSPLANT DYSFUNCTION OF TRANSPLANTED ISLETS IN RATS RECEIVING A MARGINAL ISLET MASS.
Saudek Pancreatic Islet Transplantation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee